Top Page
Genscript Biotech
(OTC:1548)
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Genscript Biotech Business Overview & Revenue Model
Genscript Biotech Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 594.49M | 839.53M | 625.70M | 490.10M | 390.85M |
| Gross Profit | 272.13M | 409.55M | 304.08M | 282.52M | 255.89M |
| EBITDA | 70.43M | -249.42M | -389.04M | -341.57M | -174.71M |
| Net Income | 2.96B | -95.48M | -226.85M | -358.71M | -204.94M |
Balance Sheet | |||||
| Total Assets | 5.28B | 3.39B | 2.55B | 2.23B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 621.18M | 1.93B | 1.46B | 1.41B | 772.38M |
| Total Debt | 723.74M | 416.99M | 349.80M | 156.45M | 55.00M |
| Total Liabilities | 954.91M | 1.34B | 1.18B | 846.17M | 631.82M |
| Stockholders Equity | 4.32B | 1.39B | 1.01B | 1.05B | 901.71M |
Cash Flow | |||||
| Free Cash Flow | -72.27M | -444.62M | -336.40M | -269.83M | -272.97M |
| Operating Cash Flow | 75.65M | -286.91M | -120.29M | -136.79M | -151.09M |
| Investing Cash Flow | -1.46B | -357.73M | -443.30M | -212.55M | -100.17M |
| Financing Cash Flow | 66.52M | 1.07B | 419.32M | 902.14M | 624.20M |
Genscript Biotech Technical Analysis
Genscript Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$36.01B | 0.97 | -6.09% | ― | ― | ― | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
| ― | €3.63B | ― | -32.29% | ― | ― | ― | |
55 Neutral | HK$38.78B | ― | -19.78% | ― | 25.96% | 39.58% | |
| ― | HK$32.76B | 41.86 | 10.27% | 1.32% | ― | ― | |
70 Outperform | HK$38.04B | 42.77 | 31.65% | ― | 4.23% | 47.71% | |
69 Neutral | HK$42.86B | 35.25 | 5.72% | 0.02% | -15.81% | -48.17% |
Genscript Biotech Corporate Events
Genscript Biotech Corporation has announced a significant expected increase in profit before tax for the first half of 2025, compared to the same period in 2024. This growth is primarily driven by a substantial rise in license revenue, particularly from LaNova Medicines Ltd., and a decrease in non-cash fair value loss from its preferred shares. The announcement highlights the company’s strategic positioning and ability to leverage its diversified business model and technological capabilities, potentially impacting its stakeholders positively.
Legend Biotech, an associate of Genscript Biotech, announced that its product CARVYKTI® generated approximately $439 million in net trade sales for the quarter ending June 30, 2025. This financial performance is linked to a collaboration with Janssen Biotech, highlighting the product’s market success and potential impact on Genscript’s financial standing and industry positioning.
Genscript Biotech Corporation announced that its subsidiary, ProBio, received approximately $213.8 million in payments under a licensing agreement with LaNova Medicines Ltd. This agreement grants LaNova an exclusive, worldwide license to develop and commercialize anti-PD-1 single domain antibodies. The payments, which include upfront and milestone payments, as well as sublicense revenue, will enhance ProBio’s cash reserves and strengthen its core competencies. The licensed antibodies demonstrate strong binding and tumor growth inhibition, comparable to Merck’s Keytruda, and have a favorable developability profile for manufacturing.
Genscript Biotech Corporation announced the grant of 624,540 Restricted Shares to its rotating chief executive officer and a director under the 2019 RSA Scheme. This move is part of the company’s strategy to align the interests of its executives with corporate performance, with vesting periods extending up to five years and performance targets in place. The inclusion of a clawback mechanism ensures that the company can reclaim equity incentives under certain conditions, such as misconduct or financial misstatements.
Legend Biotech, an associate of GenScript Biotech, announced promising five-year survival data from the CARTITUDE-1 study for its CARVYKTI® therapy in treating multiple myeloma. The data, presented at the 2025 ASCO Annual Meeting, showed that one-third of patients remained progression-free for five years, highlighting the therapy’s potential impact on long-term cancer treatment. Additionally, preliminary results from ongoing studies in solid tumors were also presented, indicating potential advancements in lung and gastric cancer therapies.
Genscript Biotech Corporation held its Annual General Meeting on May 29, 2025, where all proposed resolutions were passed by poll. Key decisions included the re-election of several directors and the reappointment of Ernst & Young as auditors. The meeting also granted the board mandates to issue and repurchase shares, reflecting strategic moves to enhance corporate governance and shareholder value.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation announced the composition and roles of its board of directors, highlighting the establishment of five committees to enhance governance and strategic oversight. This organizational update is likely to strengthen the company’s operational framework and could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation has updated the terms of reference for its Nomination Committee, emphasizing the importance of diversity and independent oversight. The committee, which consists of at least three directors with a focus on gender diversity and independent non-executive directors, is tasked with reviewing the board’s structure and skills annually to align with the company’s corporate strategy. This move aims to enhance corporate governance and ensure the board’s composition supports strategic goals, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Legend Biotech, an associate of Genscript Biotech, will present new data on CARVYKTI, a treatment for multiple myeloma, at the 2025 ASCO and EHA annual meetings. This announcement highlights the ongoing development efforts in the CARTITUDE Clinical Development Program, which could have significant implications for the treatment of multiple myeloma and potentially enhance Legend Biotech’s position in the biotech industry.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
GenScript Biotech Corporation, a company incorporated in the Cayman Islands, has announced the financial results of its associate, Legend Biotech Corporation, for the first quarter ended March 31, 2025. Legend Biotech, listed on the Nasdaq Global Selected Market, has filed its Form 6-K with the SEC, detailing its financial performance and recent business highlights. GenScript advises shareholders and potential investors to exercise caution when dealing with its securities, as the financial results pertain solely to Legend Biotech.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
Genscript Biotech Corporation has completed a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman. This transaction, which took place on May 7, 2025, strengthens Genscript’s control over Probio Cayman, increasing its equity interest to approximately 85.09%. This strategic move is likely to enhance Genscript’s market positioning and operational capabilities in the biotech sector.